Solu-Medrol (Methylprednisolone Sodium Succinate)

Solu-Medrol is a well-known brand of methylprednisolone sodium succinate, a potent anti-inflammatory glucocorticoid. This medication is primarily used to treat severe allergic reactions, certain types of arthritis, blood disorders, and various other conditions that benefit from steroid treatment.

The brand was originally developed by The Upjohn Company, which pioneered many corticosteroid formulations in the mid-20th century. Over the decades, through a series of pharmaceutical industry mergers—including the 1995 merger with Pharmacia and the subsequent 2003 acquisition by Pfizer—the brand has become a staple of Pfizer's hospital business unit. Today, while generic versions exist, the brand name Solu-Medrol remains a global standard for injectable corticosteroids. Manufacturing is primarily concentrated in the United States, specifically at Pfizer's major production facilities in Michigan, though global demand may be met by other international sites.